Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes.

Kallemeijn WW, Scheij S, Hoogendoorn S, Witte MD, Herrera Moro Chao D, van Roomen CP, Ottenhoff R, Overkleeft HS, Boot RG, Aerts JM.

PLoS One. 2017 Feb 16;12(2):e0170268. doi: 10.1371/journal.pone.0170268. eCollection 2017.

2.

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy.

Serratrice C, Carballo S, Serratrice J, Stirnemann J.

Core Evid. 2016 Oct 14;11:37-47. eCollection 2016. Review.

3.

Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options.

Van Rossum A, Holsopple M.

Hosp Pharm. 2016 Jul;51(7):553-63. doi: 10.1310/hpj5107-553.

4.

The potential of plants as a system for the development and production of human biologics.

Chen Q, Davis KR.

F1000Res. 2016 May 19;5. pii: F1000 Faculty Rev-912. doi: 10.12688/f1000research.8010.1. eCollection 2016. Review.

5.

Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.

Zimran A, Durán G, Mehta A, Giraldo P, Rosenbaum H, Giona F, Amato DJ, Petakov M, Muñoz ET, Solorio-Meza SE, Cooper PA, Varughese S, Chertkoff R, Brill-Almon E.

Am J Hematol. 2016 Jul;91(7):656-60. doi: 10.1002/ajh.24369. Epub 2016 Apr 24.

6.

Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.

Pastores GM, Shankar SP, Petakov M, Giraldo P, Rosenbaum H, Amato DJ, Szer J, Chertkoff R, Brill-Almon E, Zimran A.

Am J Hematol. 2016 Jul;91(7):661-5. doi: 10.1002/ajh.24399. Epub 2016 May 18.

7.

Putting the Spotlight Back on Plant Suspension Cultures.

Santos RB, Abranches R, Fischer R, Sack M, Holland T.

Front Plant Sci. 2016 Mar 11;7:297. doi: 10.3389/fpls.2016.00297. eCollection 2016. Review.

8.

Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.

Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, Hollak CE, Aerts JM.

Orphanet J Rare Dis. 2016 Mar 24;11:28. doi: 10.1186/s13023-016-0413-3.

9.

Plant-based vaccines for animals and humans: recent advances in technology and clinical trials.

Takeyama N, Kiyono H, Yuki Y.

Ther Adv Vaccines. 2015 Sep;3(5-6):139-54. doi: 10.1177/2051013615613272. Review.

10.

Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants.

Loos A, Gach JS, Hackl T, Maresch D, Henkel T, Porodko A, Bui-Minh D, Sommeregger W, Wozniak-Knopp G, Forthal DN, Altmann F, Steinkellner H, Mach L.

Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12675-80. doi: 10.1073/pnas.1509090112. Epub 2015 Sep 28.

11.

RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapies.

Acosta W, Ayala J, Dolan MC, Cramer CL.

Sci Rep. 2015 Sep 18;5:14144. doi: 10.1038/srep14144.

12.

Molecular pharming's foot in the FDA's door: Protalix's trailblazing story.

Mor TS.

Biotechnol Lett. 2015 Nov;37(11):2147-50. doi: 10.1007/s10529-015-1908-z. Epub 2015 Jul 7. Review.

13.

Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.

Abbas R, Park G, Damle B, Chertkoff R, Alon S.

PLoS One. 2015 Jun 8;10(6):e0128986. doi: 10.1371/journal.pone.0128986. eCollection 2015.

14.

A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.

Choi JH, Lee BH, Ko JM, Sohn YB, Lee JS, Kim GH, Heo SH, Park JY, Kim YM, Kim JH, Yoo HW.

J Korean Med Sci. 2015 Apr;30(4):378-84. doi: 10.3346/jkms.2015.30.4.378. Epub 2015 Mar 19. Erratum in: J Korean Med Sci. 2015 Sep;30(9):1373.

15.

Gaucher disease.

Nagral A.

J Clin Exp Hepatol. 2014 Mar;4(1):37-50. doi: 10.1016/j.jceh.2014.02.005. Epub 2014 Apr 21. Review.

16.
17.

Plant glyco-biotechnology on the way to synthetic biology.

Loos A, Steinkellner H.

Front Plant Sci. 2014 Oct 8;5:523. doi: 10.3389/fpls.2014.00523. eCollection 2014. Review.

18.

Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension.

Shenoy V, Kwon KC, Rathinasabapathy A, Lin S, Jin G, Song C, Shil P, Nair A, Qi Y, Li Q, Francis J, Katovich MJ, Daniell H, Raizada MK.

Hypertension. 2014 Dec;64(6):1248-59. doi: 10.1161/HYPERTENSIONAHA.114.03871. Epub 2014 Sep 15. Erratum in: Hypertension. 2015 Mar;65(3):e8.

19.

Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.

Vigan M, Stirnemann J, Caillaud C, Froissart R, Boutten A, Fantin B, Belmatoug N, Mentré F.

Orphanet J Rare Dis. 2014 Jun 30;9:95. doi: 10.1186/1750-1172-9-95.

20.

Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice.

Whitehead M, Ohlschläger P, Almajhdi FN, Alloza L, Marzábal P, Meyers AE, Hitzeroth II, Rybicki EP.

BMC Cancer. 2014 May 24;14:367. doi: 10.1186/1471-2407-14-367.

Supplemental Content

Support Center